兰索拉唑
雷尼替丁
医学
质子抑制剂泵
胃肠病学
内科学
回流
不利影响
食管炎
奥美拉唑
疾病
作者
Malcolm Robinson,Bruce Sahba,Dennis L. Avner,N. Jhala,P. A. GRESKI‐ROSE,Dennis E. Jennings
标识
DOI:10.1111/j.1365-2036.1995.tb00347.x
摘要
Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity. The aim of this study was to compare lansoprazole to a standard dose of ranitidine in the treatment of patients with reflux oesophagitis.Two hundred and forty-seven patients with erosive oesophagitis were randomly assigned to 8 weeks of treatment with either 30 mg lansoprazole once daily or 150 mg ranitidine twice daily.Two hundred and forty-two patients were included in the analysis. Lansoprazole (30 mg) daily, healed oesophagitis in 92.1% of patients after 8 weeks of treatment. This was significantly superior to 150 mg ranitidine b.d.s. which healed oesophagitis in 69.9% of patients (P < 0.001). Relief of reflux symptoms was superior with lansoprazole to that with ranitidine. Both lansoprazole and ranitidine were well tolerated with no serious drug-related adverse events noted.Lansoprazole, 30 mg once daily, is highly effective and safe in the short-term treatment of erosive oesophagitis.
科研通智能强力驱动
Strongly Powered by AbleSci AI